Retifanlimab – March 2026

Solution concentrate for I.V. infusion 500 mg in 20 mL

  • Brand names:
    • Zynyz®
  • Pharmaceutical Company:
    • SPECIALISED THERAPEUTICS ALIM PTY LTD
  • Condition/Indication: Squamous cell anal carcinoma (SCAC)
  • Meeting Date: March 2026
Public Summary Documents
Related Public Summary Documents
Last updated
11 March 2026